KIM-ANH DO to Survival Analysis
This is a "connection" page, showing publications KIM-ANH DO has written about Survival Analysis.
Connection Strength
0.229
-
Integrative network-based Bayesian analysis of diverse genomics data. BMC Bioinformatics. 2013; 14 Suppl 13:S8.
Score: 0.050
-
Bayesian ensemble methods for survival prediction in gene expression data. Bioinformatics. 2011 Feb 01; 27(3):359-67.
Score: 0.041
-
A Bayesian semiparametric survival model with longitudinal markers. Biometrics. 2010 Jun; 66(2):435-43.
Score: 0.037
-
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014 Nov 13; 124(20):3059-64.
Score: 0.013
-
Diet modification and metformin have a beneficial effect in a fly model of obesity and mucormycosis. PLoS One. 2014; 9(9):e108635.
Score: 0.013
-
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res. 2008 Jun 15; 14(12):3729-36.
Score: 0.009
-
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008 Aug 15; 112(4):975-80.
Score: 0.009
-
Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006 Jul 01; 107(1):125-35.
Score: 0.008
-
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006 May 20; 24(15):2343-51.
Score: 0.008
-
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4070-8.
Score: 0.007
-
Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res. 2004 Oct 15; 10(20):6770-8.
Score: 0.007
-
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003 Apr 01; 101(7):2507-13.
Score: 0.006
-
Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer. 2002 May 20; 86(10):1555-60.
Score: 0.006
-
Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg. 2002 May; 235(5):722-30; discussion 730-1.
Score: 0.006
-
A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. Ann Oncol. 2002 Jan; 13(1):125-34.
Score: 0.006
-
Reconstructive management of cranial base defects after tumor ablation. Plast Reconstr Surg. 2001 May; 107(6):1346-55; discussion 1356-7.
Score: 0.005